Some studies also indicate that SGLT1 targeting agents (Phlorizin or RNAi) may act as a novel adjuvant therapy for cancer treatment via the disruption of SGLT1/EGFR interaction [208,209,210]. This evidence concerns the gene SLC5A1 and cancer.